ArticleAnnals of medicine2025
Imbalance between skeletal muscle and intermuscular fat predicts treatment failure in Crohn's disease: an imaging biomarker for risk stratification.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Sarcopenia in Inflammatory Bowel Disease: Prevalence, Mechanisms, Detection, Adverse Clinical Impact and Targetable Care Gaps-A Narrative Review Supported by a Structured Literature Search.Life (Basel, Switzerland) · 2026Review
- Beyond Inflammation: Sarcopenia and Disease Phenotype Predict Unfavourable Course in Crohn's Disease-A Retrospective Observational Study.Biomedicines · 2026Article
- Predictive model for vedolizumab efficacy in moderate-to-severe ulcerative colitis based on computed tomography-derived body compositions and nutritional inflammatory markers.World journal of radiology · 2026Article
- Association of magnesium depletion score, triglyceride-glucose index, and C-reactive protein-albumin-lymphocyte index with diabetic sarcopenia: a cross-sectional study based on NHANES 2014-2018 data.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSarcopenia is prevalent in Crohn's disease (CD) patients, but the prognostic value of skeletal muscle-to-intermuscular adipose tissue (IMAT) balance in penetrating CD remains unexplored.
objectiveTo determine whether skeletal muscle-IMAT imbalance predicts non-surgical treatment failure in CD.
methodsThis retrospective study included CD patients undergoing computed tomography enterography (CTE, 2013-2022), stratified by disease behavior (penetrating vs. non-penetrating). Automated CTE segmentation algorithm quantified skeletal muscle and IMAT volumes at baseline. Skeletal muscle ratio was calculated as skeletal muscle/(skeletal muscle + IMAT). Sarcopenia was defined by the skeletal muscle area at the third lumbar vertebra. Patients received ≥1 year of non-surgical therapy, with outcomes categorized as 'maintenance therapy' or 'treatment escalation'. Cox proportional hazards analysis identified predictors of escalation; mediation analysis evaluated inflammatory-nutritional pathways.
resultsAmong 157 patients (penetrating:
conclusionsSkeletal muscle-IMAT imbalance independently predicts treatment escalation in CD, offering superior prognostic utility to traditional sarcopenia measures.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.